Results 211 to 220 of about 37,295 (243)

Phase II trial of thalidomide in renal-cell carcinoma

Annals of Oncology, 2002
Eric Angevin, Agnes Laplanche, Dominique Couanet   +2 more
exaly  

Non-thromboembolic pulmonary hypertension in multiple myeloma, after thalidomide treatment: A pilot study

Annals of Oncology, 2008
K Zervas
exaly  

THALIDOMIDE AND AFTER

Developmental Medicine & Child Neurology, 1962
openaire   +2 more sources

Inhibition of Angiogenesis by Thalidomide Requires Metabolic Activation, Which Is Species-dependent

Biochemical Pharmacology, 1998
Shannon C Dixon, W D Figg
exaly  

THALIDOMIDE AND LEPROSY

The Lancet, 1985
openaire   +2 more sources

Thalidomide's chirality

Nature, 1997
S, Wnendt, K, Zwingenberger
openaire   +2 more sources

Teratogenic effects of thalidomide: molecular mechanisms

Cellular and Molecular Life Sciences, 2011
Hiroshi Handa, Takumi Ito, Hideki Ando
exaly  

The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis

Blood, 2012
Mark T Drayson, Faith E Davies, Gareth J. Morgan   +2 more
exaly  

THALIDOMIDE IN JAPAN

The Lancet, 1963
T, KAJII, M, SHINOHARA
openaire   +2 more sources

Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes.

Journal of Experimental Medicine, 1991
Gilla Kaplan, Elizabeth P Sampaio, Z A Cohn   +2 more
exaly